- 作者：Prof Michael Untch ; MDa ; Sibylle Loibl ; MDb ; Joachim Bischoff ; MDc ; Holger Eidtmann ; MDd ; Prof Manfred Kaufmann ; MDe ; Prof Jens-Uwe Blohmer ; MDf ; Prof Jö ; rn Hilfrich ; MDg ; Prof Dirk Strumberg ; MDh ; Prof Peter A Fasching ; MDi ; j ; Prof Rolf Kreienberg ; MDk ; Prof Hans Tesch ; MDl ; Claus Hanusch ; MDm ; Prof Bernd Gerber ; MDn ; Mahdi Rezai ; MDo ; Prof Christian Jackisch ; MDp ; Prof Jens Huober ; MDq ; Prof Thorsten Kü ; hn ; MDr ; Valentina Nekljudova ; PhDb ; Prof Gunter von Minckwitz ; MDb ; gunter.vonminckwitz@germanbreastgroup.de ; for the German Breast Group (GBG) ; the Arbeitsgemeinschaft Gynä ; kologische Onkologie-Breast (AGO-B) Study Group
- 刊名：Lancet Oncology
- 出版年：2012
- 出版时间：February 2012
- 年：2012
- 卷：13
- 期：2
- 页码：135-144
- 全文大小：264 K
Summary
Background
We compared the efficacy and safety of the addition of lapatinib versus trastuzumab to anthracycline-taxane-based neoadjuvant chemotherapy.Methods
In the GeparQuinto randomised phase 3 trial, patients with untreated HER2-positive operable or locally advanced breast cancer were enrolled between Nov 7, 2007, and July 9, 2010. Patients were eligible if their tumours were classified as cT3/4a-d, or hormone receptor (HR)-negative, HR-positive with clinically node-positive and cT2 disease (cT2 cN+), or HR-positive and pathologically node-positive in the sentinel lymph node for those with cT1 disease (cT1 pNSLN+). Patients were randomly assigned in a 1:1 ratio to receive neoadjuvant treatment with four cycles of EC (epirubicin [90 mg/m2 intravenously] plus cyclophosphamide [600 mg/m2 intravenously], every 3 weeks), and four cycles of docetaxel (100 mg/m2 intravenously every 3 weeks) with either trastuzumab (6 mg/kg intravenously, with a starting loading dose of 8 mg/kg, for eight cycles, every 3 weeks) or lapatinib (1000-1250 mg per day orally) throughout all cycles before surgery. Randomisation was done by dynamic allocation with the minimisation method of Pocock and patients were stratified by participating site, HR status, and extent of disease (cT1-3 cN0-2 vs T4 or N3). The primary endpoint was pathological complete response (defined as ypT0 and ypN0) and was analysed in all patients who received at least one cycle of EC. Participants and investigators were not masked to treatment assignment. Pathologists in centres assessing surgery outcomes were masked to group assignment. This trial is registered with , number .
Findings
Of 620 eligible patients, 309 were randomly assigned to chemotherapy with trastuzumab (ECH-TH group) and 311 to chemotherapy with lapatinib (ECL-TL group). Two patients in the ECH-TH group and three patients in the ECL-TL group did not start treatment because of withdrawal of consent or immediate surgery. 93 (30¡¤3 % ) of 307 patients in the ECH-TH group and 70 (22¡¤7 % ) of 308 patients in the ECL-TL group had a pathological complete response (odds ratio [OR] 0¡¤68 [95 % CI 0¡¤47-0¡¤97]; p=0¡¤04). Chemotherapy with trastuzumab was associated with more oedema (119 [39¡¤1 % ] vs 88 [28¡¤7 % ]) and dyspnoea (90 [29¡¤6 % ] vs 66 [21¡¤4 % ]), and ECL-TL with more diarrhoea (231 [75¡¤0 % ] vs 144 [47¡¤4 % ]) and skin rash (169 [54¡¤9 % ] vs 97 [31¡¤9 % ]). 43 (14¡¤0 % ) patients discontinued in the ECH-TH group and 102 (33¡¤1 % ) in the ECL-TL group. 70 serious adverse events were reported in the ECH-TH group and 87 in the ECL-TL group.
Interpretation
This direct comparison of trastuzumab and lapatinib showed that pathological complete response rate with chemotherapy and lapatinib was significantly lower than that with chemotherapy and trastuzumab. Unless long-term outcome data show different results, lapatinib should not be used outside of clinical trials as single anti-HER2-treatment in combination with neoadjuvant chemotherapy.
Funding
GlaxoSmithKline, Roche, and Sanofi-Aventis.